ProCE Banner Activity

Pretreatment ctDNA and Additional Factors Associated With Disease Recurrence in Stage IIIB-D/IV Melanoma Treated With Adjuvant Immunotherapy in CheckMate 915

Slideset Download
Conference Coverage
Retrospective analyses from the CheckMate 915 study showed that ctDNA positivity and other translational factors at baseline were associated with a worse RFS in patients with resected stage IIIB-D/IV melanoma who received adjuvant nivolumab with or without ipilimumab.

Released: September 23, 2022

Expiration: September 22, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.